Please login to the form below

Not currently logged in
Email:
Password:

Ark Therapeutics

This page shows the latest Ark Therapeutics news and features for those working in and with pharma, biotech and healthcare.

Emas appoints Dr Neil Murray

Prior to this he was head of clinical development at Ark Therapeutics and global head of pharmacovigilance at F.Hoffmann-La Roche.

Latest news

  • MSD invests in FKD Therapies

    MSD has taken an equity stake in the Finland based company, FKD Therapies, owned by former CEO of Ark Therapeutics Nigel Parker. ... FKD Therapies, which has reserves of $16m, is a company started by Nigel Parker, the former chief executive of Ark

  • Ark files documentation on Cerepro

    Ark Therapeutics Group has requested re-examination of the marketing approval application for its brain cancer drug, Cerepro, from the EMA. ... Ark Therapeutics Group has filed documentation with the European Medicines Agency (EMA) in relation to its

  • Close but no cigar

    A number of promising candidates include Introgen's contusugene ladenovec (ADVEXIN), an adenoviral p53 gene therapy, and Ark Therapeutics' sitimagene ceradenovec (Cerepro). ... Another candidate under regulatory review is sitimagene ceradenovec (Cerepro),

  • R&D news in brief

    Ark reveals new R&D head. David Eckland has been appointed head of research and development at Ark Therapeutics, the company has revealed. ... Ark Therapeutics is a spin-out biotech company from University College London and successfully floated on the

  • R&D news in brief

    to scientists working in Finland for UK biotech firm Ark Therapeutics. ... While, until now, gene therapy delivery has relied on the insertion of DNA almost at random into human chromosomes, Ark said it was using targeting molecules, known as integrase

More from news
Approximately 0 fully matching, plus 22 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Skills in Healthcare

At Skills in Healthcare, we are able to provide our customers with a professional set of sales capabilities. With our...

Latest intelligence

Is China ready for a pharmaceutical gold rush?
Some describe doing business in China as akin to the 1990s internet boom – so how stable is its future?...
AstraZeneca’s oncology renaissance
Susan Galbraith played a key role in restoring AstraZeneca’s place in cancer drug development – she talks about the future of oncology and why there’s more to be done to...
Navigating the antibiotic resistance crisis
Blue Latitude Health speaks to Tara DeBoer, PhD, Postdoctoral Researcher and CEO of BioAmp Diagnostics to explore the antimicrobial resistance crisis, and learn how a simple tool could support physicians...

Infographics